Skip to main content
Benaroya Research Institute at Virginia Mason logo.
Menu
  • News
  • Resources
  • Careers
  • Autoimmune Life Blog
  • Contact

Search form

  • What is BRI
    • About BRI
    • Immune System Diseases
    • Scientists & Laboratories
  • Research at BRI
    • Join Our Research
    • Track Our Clinical Research
    • Type 1 Diabetes Research
    • Centers of Discovery
    • Programs
    • Recent Publications
    • Collaborations
  • For Scientists
    • Programs
    • Core Labs
    • Principal Scientist Labs
    • Scientific Staff
    • Publications
  • For Industry
    • Contact Us
    • Business Development Team
    • Available Technologies
    • Industry Collaborations
    • Clinical Research Program -- for Sponsors
  • Support BRI
    • BRI Fundraising Events
    • Become a Champion
    • Ways to Give

Donate

You are here

Home / Research at BRI / Track Our Clinical Research / Currently Enrolling Studies / Cancer

Track Our Clinical Research

Hepatobiliary Cancer

Contact: CancerResearch@VirginiaMason.org ; (206) 287-6270

Clinical StudiesDiagnosis
Non-MetastaticMetastaticPreviously TreatedTreatment Naive

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

 ✔ ✔

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

 ✔ ✔
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEY NOTE-937) ✔ ✔
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma    
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis ✔ ✔
VM BRITE: A Tissue Registry and Specimen Repository to Support Future Research Projects✔✔✔✔

Research at BRI

  • Join Our Research
  • Track Our Clinical Research
    • Why Participate in Clinical Research?
    • Currently Enrolling Studies
      • Allergies & Asthma
      • Anesthesiology
      • Cancer
      • Cardiology
      • Diabetes
      • Gastroenterology
      • Gynecology
      • Liver Disease
      • Neurological Diseases
      • Rheumatic Diseases
      • Surgery
      • Urology
    • Clinical Research Program - for Sponsors
  • Type 1 Diabetes Research
  • Centers of Discovery
  • Programs
  • Recent Publications
  • Collaborations

What is BRI

  • About the Institute
  • Disease Information
  • Scientists & Labs

Our Research

  • Diabetes Research
  • Biorepositories
  • Programs
  • Publications
  • Clinical Research

Newsroom

  • Autoimmune Life Blog
  • Announcements
  • In the News
  • Press Releases

Resources

  • Contact Info
  • Sign Up
  • Careers
  • Educational Opportunities
  • Community Involvement

Support

  • BRI Events
  • Become a Champion
  • Ways to Give
  • Fundraise for BRI
  • Donate Now
Benaroya Research Institute at Virginia Mason

Terms of Use Privacy Policy

© 2022 Benaroya Research Institute at Virginia Mason. 1201 Ninth Avenue, Seattle, WA 98101-2795

(206) 342-6500

  • Twitter
  • Facebook
  • LinkedIn
  • YouTube
  • Instagram